Journal: Blood cancer journal
This publication reviews the emerging use of frontline triplet therapies for treating acute myeloid leukemia (AML) in older or unfit patients. These therapies combine venetoclax-based doublets (azacitidine or low-dose cytarabine) with targeted agents (FLT3, IDH, or menin inhibitors).
These triplet regimens show promising results, including:
- Composite complete remission
- Measurable residual disease negativity rates
- Facilitation of allogeneic stem cell transplantation for eligible patients
However, increased myelosuppression and cytopenia-associated toxicities pose challenges to tolerability and quality of life.
The review provides evidence-based recommendations on:
- Dosing adjustments during induction and continuation phases
- Drug-specific adverse effects and interactions
These guidelines aim to help clinicians optimize treatment with these novel combinations.